Literature DB >> 26153219

Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab.

Yuliya Hellwig1, Young E Yoo1, Marie L Reß1, Oliver Andres1, Matthias Braun1, Paul G Schlegel1, Matthias Wölfl1.   

Abstract

Acute Graft-versus-Host-Disease (GvHD) is a potentially life-threatening complication after allogeneic stem cell transplantation. If not treated early and adequately, the complex immunological mechanisms may lead to a self-perpetuating cycle of alloreactivity, which is then associated with a high mortality. Here we assessed the cytokine profile on a daily basis in a patient with grade 4 skin GvHD, demonstrating a signature resembling cytokine-release-syndrome. After multimodal immunosuppressive intervention, including treatment with the IL6 receptor-blocking antibody tocilizumab, the severe clinical symptoms unexpectedly resolved within 48 hr.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute GvHD; cytokine profile; cytokine release syndrome; stem cell transplantation; tocilizumab

Mesh:

Substances:

Year:  2015        PMID: 26153219     DOI: 10.1002/pbc.25595

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  The continuing evolution of targeted therapy for inflammatory skin disease.

Authors:  C Schlapbach; A A Navarini
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

2.  Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

Authors:  Shoko Mori; Alanna Hickey; Stephen W Dusza; Mario E Lacouture; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2018-10-26       Impact factor: 11.527

3.  Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation.

Authors:  Xinhua Chen; Xueqin Meng; Yuning Xu; Haiyang Xie; Shengyong Yin; Hongchun Li; Liming Wu; Shusen Zheng
Journal:  Eur J Med Res       Date:  2016-10-12       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.